EFFECT OF ACUTE AND CHRONIC ADMINISTRATION OF BUSPIRONE ON SEROTONIN AND BENZODIAZEPINE RECEPTOR SUBTYPES IN THE RAT-BRAIN - AN AUTORADIOGRAPHIC STUDY

被引:32
作者
GOBBI, M [1 ]
CAVANUS, S [1 ]
MIARI, A [1 ]
MENNINI, T [1 ]
机构
[1] MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY
关键词
ANXIOLYTIC DRUGS; BUSPIRONE; SEROTONIN RECEPTORS; BENZODIAZEPINE RECEPTORS; AUTORADIOGRAPHY;
D O I
10.1016/0028-3908(91)90055-G
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
The affinity of buspirone and its main metabolite 1-(2-pyrimidinyl)piperazine (PmP) for serotonin1 (5-HT1) and benzodiazepine receptors was first evaluated by computerized receptor autoradiography. The results confirmed that buspirone is a selective 5-HT1A ligand, since it inhibited the binding of [H-3]5-HT with lower IC50 values (about 100 nM) in regions of the brain of the rat where this receptor subtype is predominant (such as hippocampal areas). Larger IC50 values than 3-mu-M were found in areas of the brain richer in 5-HT1 receptors, other than the 5-HT1A subtype (e.g. striatum, substantia nigra and the ventricles). The PmP was not selective, inhibiting the binding of [H-3]5-HT with similar affinity (about 4-10-mu-M) in all the regions of the brain examined. Neither buspirone nor PmP, up to 100-mu-M, were active on benzodiazepine receptors. The autoradiographic technique was therefore used to evaluate the effects of acute (10 mg/kg, p.o., 1 hr before killing) and chronic (10 mg/kg, i.p., twice a day for 21 days, 24 hr washout) treatment with buspirone in male rats. Acute treatment reduced the binding of [H-3]5-HT in all the regions of the brain studied, including those with low levels of 5-HT1A receptors, indicating the occupancy of 5-HT1 receptors by either buspirone or its metabolite. The binding of [H-3]flunitrazepam was decreased (16%) only in the substantia nigra. The benzodiazepine/GABA receptors present in the substantia nigra, also undergo adaptive changes after chronic treatment with buspirone: only in this region was binding to benzodiazepine receptors increased by 41% (mainly due to type I receptors) and GABA partly lost its enhancing efficacy. Moreover, chronic administration of buspirone significantly reduced (21%) the binding of [H-3]5-HT to 5-HT1A receptors in the dorsal raphe, whereas a significant increase in binding of [H-3]5-HT (32%) was found in the substantia nigra, which was unrelated to any modification of 5-HT1A receptors. No significant changes were evident in the other regions of the brain.
引用
收藏
页码:313 / 321
页数:9
相关论文
共 30 条
[1]   MODIFICATION OF 5-HT NEURON PROPERTIES BY SUSTAINED ADMINISTRATION OF THE 5-HT1A AGONIST GEPIRONE - ELECTROPHYSIOLOGICAL STUDIES IN THE RAT-BRAIN [J].
BLIER, P ;
DEMONTIGNY, C .
SYNAPSE, 1987, 1 (05) :470-480
[2]   1-(2-PYRIMIDINYL)-PIPERAZINE AS ACTIVE METABOLITE OF BUSPIRONE IN MAN AND RAT [J].
CACCIA, S ;
CONTI, I ;
VIGANO, G ;
GARATTINI, S .
PHARMACOLOGY, 1986, 33 (01) :46-51
[3]   POTENTIAL ANXIOLYTIC PROPERTIES OF 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN, A SELECTIVE SEROTONIN1A RECEPTOR AGONIST [J].
CARLI, M ;
SAMANIN, R .
PSYCHOPHARMACOLOGY, 1988, 94 (01) :84-91
[4]  
CIMINO M, 1983, BIOCHEM PHARMACOL, V32, P1069, DOI 10.1016/0006-2952(83)90627-5
[5]   FUNCTIONAL COUPLING OF GABAA RECEPTORS AND BENZODIAZEPINE RECOGNITION SITE SUBTYPES IN THE SPINAL-CORD OF THE RAT [J].
CORDA, MG ;
GIORGI, O ;
LONGONI, B ;
ONGINI, E ;
PESCE, G ;
CRUCIANI, R ;
BIGGIO, G .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 169 (2-3) :205-213
[6]  
COTT JM, 1986, AM PSYCHIATR ASS, V139, pNR15
[7]  
CSANALOSI I, 1987, J CLIN PSYCHOPHARM, V7, P31
[8]   EFFECT OF BUSPIRONE AND ITS METABOLITE 1-(2-PYRIMYDINYL)-PIPERAZINE ON HIPPOCAMPAL SEROTONINERGIC SYSTEM, STUDIED IN FREELY MOVING RATS [J].
DESIMONI, MG ;
IMERI, L ;
DELUIGI, A ;
FODRITTO, F ;
GARATTINI, S .
LIFE SCIENCES, 1990, 46 (03) :197-205
[9]   ANTICONFLICT EFFECT OF THE PUTATIVE SEROTONIN RECEPTOR AGONIST 8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN (8-OH-DPAT) [J].
ENGEL, JA ;
HJORTH, S ;
SVENSSON, K ;
CARLSSON, A ;
LILJEQUIST, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 105 (3-4) :365-368
[10]  
FEIGHNER JP, 1982, J CLIN PSYCHIAT, V43, P103